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Calcitonin gene-related peptide (CGRP) seems to play a
major role in migraine mechanism. Overwhelming data
report the efficacy of small molecule CGRP receptor
antagonists in the treatment of migraine attacks. If some
CGRP receptor (CGRP-R) antagonists could theoretically
cross the blood brain barrier (BBB) one of them, olcage-
pant, due to its peptoid nature could not. However, the
clinical development of such otherwise well tolerated com-
pounds has been spoiled by their hepatic liability that has
been considered an off-target effect. In the last few years
the identification of monoclonal antibodies (Ab) for CGRP
or the CGRP-R has provided an alternative strategy to
maintain a good efficacy profile and circumvent the severe
liver toxicity of classical small molecules CGRP-R antago-
nists. Indeed, data from phase-II trials are showing that
the therapeutic gain between active treatment with the
various anti-CGRP Abs and placebo varies from about
20% to 40% and adverse reactions are limited to irritation
at the site of injection and few other minor effects. Anti-
CGRP mAbs predictably may cross the BBB at a minimum
extent, thus making unlikely the hypothesis that they act at
sites of action within the central nervous system. This
observation is associated with the prevalent localization of
the complex multimeric assembly of CGRP-R in the
vascular smooth muscle where they mediate the inflam-
matory neurogenic vasodilatation. Thus, the most parsi-
monious hypothesis proposes that blockade of the CGRP/
CGRP-R receptor system within the cranial neurovascular
system produces the desirable analgesic effect in migraine
pain.
If the mechanism and the genetic background that by
promoting cranial neurogenic vasodilatation generate
migraine pain remain a mystery, some insights on the trig-
gers that may activate this pathogenic pathway are now
better understood. A series of agents known to provoke
migraine attacks have been identified as activators of
certain transient receptor potential (TRP) channels
expressed by a subpopulation of peptidergic nociceptors.
In particular, the subtypes ankyrin 1 (TRPA1) and vanil-
loid 1 (TRPV1) are activated by migraine provoking
agents. Nitric oxide, umbellulone and acrolein gate
TRPA1 and alcohol TRPV1. All stimuli by channel target-
ing generate CGRP release from perivascular terminals of
cranial sensory neurons, thus producing the neurogenic
effect blunted by CGRP-R antagonists and by anti CGRP
mAbs. More importantly, antimigraine medicines, such as
metamizole (dipyrone), propyphenazone and parthenolide
exert their analgesic effect by antagonizing TRPA1.
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